CIBC Asset Management Inc Purchases 92,389 Shares of Johnson & Johnson (NYSE:JNJ)

CIBC Asset Management Inc raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 727,111 shares of the company's stock after purchasing an additional 92,389 shares during the period. CIBC Asset Management Inc's holdings in Johnson & Johnson were worth $105,139,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of JNJ. KLCM Advisors Inc. lifted its stake in shares of Johnson & Johnson by 2.0% during the 4th quarter. KLCM Advisors Inc. now owns 7,186 shares of the company's stock worth $1,039,000 after buying an additional 140 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $2,629,000. Americana Partners LLC grew its holdings in shares of Johnson & Johnson by 141.4% during the 4th quarter. Americana Partners LLC now owns 185,084 shares of the company's stock valued at $26,767,000 after purchasing an additional 108,399 shares during the last quarter. Opus Capital Group LLC grew its holdings in shares of Johnson & Johnson by 79.2% during the 4th quarter. Opus Capital Group LLC now owns 3,939 shares of the company's stock valued at $570,000 after purchasing an additional 1,741 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $295,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.7 %

NYSE:JNJ traded up $2.67 during midday trading on Friday, hitting $162.35. 12,540,171 shares of the company traded hands, compared to its average volume of 9,073,381. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm's fifty day moving average is $148.61 and its 200-day moving average is $155.89. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The firm has a market capitalization of $390.87 billion, a P/E ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Citigroup reduced their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Bank of America decreased their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective for the company. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $170.67.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.